[go: up one dir, main page]

WO1998001150A1 - Interleukine 8 utilisee comme agent antiviral ou anticancereux - Google Patents

Interleukine 8 utilisee comme agent antiviral ou anticancereux Download PDF

Info

Publication number
WO1998001150A1
WO1998001150A1 PCT/CA1997/000479 CA9700479W WO9801150A1 WO 1998001150 A1 WO1998001150 A1 WO 1998001150A1 CA 9700479 W CA9700479 W CA 9700479W WO 9801150 A1 WO9801150 A1 WO 9801150A1
Authority
WO
WIPO (PCT)
Prior art keywords
agent
use according
group
interleukin
viral infection
Prior art date
Application number
PCT/CA1997/000479
Other languages
English (en)
Inventor
Jean Gosselin
Pierre Borgeat
Bassam Damaj
Original Assignee
Virocell, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Virocell, Inc. filed Critical Virocell, Inc.
Priority to JP10504609A priority Critical patent/JP2000514066A/ja
Priority to DE69718911T priority patent/DE69718911T2/de
Priority to AT97929060T priority patent/ATE232108T1/de
Priority to NZ333605A priority patent/NZ333605A/xx
Priority to AU33314/97A priority patent/AU713675B2/en
Priority to EP97929060A priority patent/EP0909178B1/fr
Priority to BR9710206A priority patent/BR9710206A/pt
Publication of WO1998001150A1 publication Critical patent/WO1998001150A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2053—IL-8
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S930/00—Peptide or protein sequence
    • Y10S930/01—Peptide or protein sequence
    • Y10S930/14—Lymphokine; related peptides
    • Y10S930/141—Interleukin

Definitions

  • the present invention is concerned with antiviral and anticancer activities of interleukin-8 (IL-8) and its use as a therapeutic agent in viral infections caused by human and animal viruses and in cancers caused by oncoviruses .
  • IL-8 interleukin-8
  • viruses Many important infectious diseases afflicting centuries are caused by viruses of which some are frequently fatal; among such are rabies, smallpox, poliomyelitis, hepatitis, yellow fever, immune deficiencies and various encephalitic diseases. Others are significant in that they are highly contagious and create acute discomfort such as influenza, measles, mumps and chickenpox, as well as respiratory- gastrointestinal disorders. Others such as rubella and cytomegalovirus can cause congenital abnormalities; finally, there are viruses, known as oncoviruses, that can cause tumors and cancer in humans and animals.
  • Herpes viruses are highly disseminated in nature and highly pathogenic for man.
  • Epstein-Barr virus (EBV) is known to cause infectious mononucleosis in late childhood or adolescence or in young adults .
  • the hallmarks of acute infectious mononucleosis are sore throat, fever, headache, lymphadenopathy, enlarged tonsils and atypical, dividing lymphocytes in the peripheral blood.
  • Other manifestations frequently include mild hepatitis, splenomegaly and cerebritis.
  • EBV is also associated with two forms of cancer: Burkitt' ⁇ lymphoma (BL) and the nasopharyngeal carcinoma (NPC).
  • BL Burkitt' ⁇ lymphoma
  • NPC nasopharyngeal carcinoma
  • BL In endemic areas of equatorial Africa, BL is the most common childhood malignancy, accounting for approximately 80% of cancers in children. While moderately observed in North American Caucasians, NPC is one of the most common cancers in Southern China with age incidence of 25 to 55 years. EBV, like the cytomegalovirus, is also associated with post-transplant lymphoproliferative disease, which is a potentially fatal complication of chronic immunosuppression following solid organ or bone marrow transplantation.
  • HSV-1 Herpes Simplex type 1
  • HSV-2 Herpes Simplex type 1
  • This HSV infection is accompanied by vesicles, pustules and ulcers causing lesions on genital parts.
  • a urinary retention syndrome may also be encountered.
  • HSV-1 or HSV-2 More than 80% of people are seropositive to HSV-1 or HSV-2 and studies have indicated a frequency of recurrence or viral reactivation as high as 60%.
  • Other diseases are also associated with HSV including skin and eye infections, for example, chorioretinitis or keratoconjunctivitis .
  • chorioretinitis or keratoconjunctivitis Approximately 300,000 cases of HSV infections of the eye are diagnosed yearly in the United States of America.
  • HHV-6 Human Herpes virus-6
  • HAV-1 human immunodeficiency virus
  • KS Kaposi sarcoma
  • herpes viruses indeed, the ability of all herpes viruses to establish latent infections results in an extremely high incidence of reactivated infection in i ⁇ ununocompromised patients.
  • renal transplant recipients 40% to 70% reactivate latent HSV infections, and 80% to 100% reactivate CMV infections.
  • Such viral reactivations have also been observed in HIV-positive patients (AIDS).
  • AIDS HIV-positive patients
  • the number of therapeutic agents available for the treatment of viral infections remains relatively limited.
  • four major compounds are mainly used in the treatment of herpes virus infections: idoxuridine, vidarabine, acyclovir and ganciclovir. Their efficacy is limited and they cause many side effects.
  • Allergic effects have been reported in 35% of patients treated with idoxuridine which is used only to treat HSV infection of the eye.
  • the most common side effects of vidarabine are gastrointestinal disturbances (15% of patients).
  • the major side effect of acyclovir is the alteration of renal function; and because acyclovir is a nucleoside analog that can be incorporated in both viral and the host cell DNA, normal division of the host cell can be affected.
  • ganciclovir the most important side effects are neutropenia and thrombocytopenia that occur in about 40% of AIDS patients.
  • the accumulation of leukocytes in diseased tissues is recognized as a hallmark of the inflammatory process. Recruitment of leukocytes at inflammatory sites is triggered by the local production of chemotactic cytokines. Proteins that exhibit such properties have been classified in two subfamilies according to the position of the first two cysteines, which either are separated by one amino acid (CXC proteins) or are adjacent ( CC proteins). The members of the two subfamilies differ in their target cell selectivity and the chromosomal location of their genes (review by Baggiolini, et al-, Adv. Immunol. 55: 97, 1994).
  • interleukin-8 which belongs to the CXC family, was originally identified in the culture supernatants of stimulated human blood monocytes.
  • IL-8 is a nonglycosylated protein synthesized as a precursor of 99 amino acids and secreted after cleavage of a sequence of 20 residues.
  • the mature molecule formed has 79 residues and is further processed proteolytically at the N- terminus, yielding several biologically active N- terminal analogs; the two major forms are the 72 amino acid form and the 77 amino acid form.
  • Structure, sequence and biological properties of IL-8 have been reviewed by Baggiolini M. et al . (Adv. Immunol. 55: 97, 1994) .
  • IL-8 is produced by many cells such as keratinocytes, epithelial cells, synoviocytes and hepatocytes, to name a few.
  • keratinocytes epithelial cells
  • synoviocytes hepatocytes
  • hepatocytes peripheral blood leukocytes
  • onocytes and neutrophils rather than lymphocytes were found to be the major cellular sources of IL-8.
  • IL-8 exerts many biological activities in vi tro and in vi vo.
  • IL-8 is well known for its chemotactic activity and its ability to cause degranulation of human neutrophils. Shape change, activation of the motile system and a rise in cytosolic free Ca 2 + are rapidly detected in neutrophils treated with IL-8. The release of vitamin Bi2 _ binding protein from specific granules was also observed.
  • IL-8 also causes degranulation of the azurophil granules and release of elastase and other hydrolases . Such degranulation is accompanied by the upregulation of a variety of adhesion molecules at the cell membrane. Degranulation also results in the enhanced expression of the complement receptor type I (CRl) and III (CR3).
  • IL-8 is also a chemotactic factor for eosinophils and for human lymphocytes, particularly T cells.
  • IL-8 receptor type A has a high affinity for IL-8 and a low affinity for Gro ⁇ (melanoma growth stimulating activity), whereas type B has high affinity for both cytokines. While among peripheral blood leukocytes, neutrophils strongly express both types of IL-8 receptors, monocytes and CD8 + T lymphocytes expressed IL-8 receptors to a lower level. No detectable level of IL-8 receptors was found on B cells and CD4 + T lymphocytes .
  • IL-8 plays an important role in the inflammatory process of many pathologies; indeed, IL-8 has been detected in inflammatory tissues or exudates such as in psoriatic scale extracts, in synovial fluid from patients with rheumatoid arthritis or gout, in pleural fluid from emphysema patients, and in bronchoalveolar lavages from patients with respiratory distress syndrome.
  • IL-8 has been detected in inflammatory tissues or exudates such as in psoriatic scale extracts, in synovial fluid from patients with rheumatoid arthritis or gout, in pleural fluid from emphysema patients, and in bronchoalveolar lavages from patients with respiratory distress syndrome.
  • antiviral properties have recently been ascribed to the chemokines RANTES and MlP-l ⁇ and ⁇ , belonging to the C-C chemokine subfamily, which were found to induce inhibition of HIV-1, HIV-2 and SIV viral protein synthesis in vi
  • IL-8 has been recently reported to have an antiviral effect (Mackewicz and Levy, 1992 AIDS Research and Human Retrovirus 8: 1039-1050). It was shown that IL-8 can inhibit HIV replication in CD4+ lymphocytes under specific conditions. In fact, IL-8 was found to affect viral replication of naturally infected CD4+ cells but had no effect on acutely infected cells .
  • Idoxuridine, Vidarabine, Acyclovir and Gangiclovir which are specifically used in the treatment of Herpes virus infection, have no effect on other viruses such as HIV, and thus constitute examples of drugs with selective antiviral activity .
  • PCT/US95/12099 published March 28, 1996 under the publication number WO 96/09062 describes polypeptide analogs of IL-8 and claims that the analogs can be used for the treatment of pathological conditions such as viral infection, bacterial infection, fungal infection, yeast infection, parasitic infection among others.
  • pathological conditions such as viral infection, bacterial infection, fungal infection, yeast infection, parasitic infection among others.
  • TALMADGE doe not present any data to prove its claim which is based on extrapolation or mere desire for the polypeptide to do so. It would be highly desirable to provide an antiviral agent with greater efficacy and which would not present the undesirable side effects of the known antiviral agents.
  • the present invention provides methods for the prophylaxis or treatment of viral infections and cancer caused by oncoviruses .
  • a pharmaceutically or physiologically acceptable, therapeutically effective amount of an interleukin-8 agent is administered to a human or animal in need of such treatment.
  • One aim of the present invention is to provide an antiviral agent and method which would be more efficacious for the prophylaxis and treatment of viral infections and which would not present the undesirable side effects of the known antiviral agents.
  • Another aim of the present invention is to provide an antiviral agent and method for the prophylaxis or treatment of cancers induced by oncoviruses such as retroviruses (excluding HIV-1 and HIV-2), papillomaviruses, adenoviruses and herpesviruses .
  • retroviruses excluding HIV-1 and HIV-2
  • papillomaviruses excluding HIV-1 and HIV-2
  • papillomaviruses excluding HIV-1 and HIV-2
  • papillomaviruses excluding HIV-1 and HIV-2
  • papillomaviruses excluding HIV-1 and HIV-2
  • adenoviruses adenoviruses
  • herpesviruses herpesviruses
  • Another aim of the present invention is to provide an antiviral agent and method for the prophylaxis or treatment of viral infections in immunosuppressed patients and animals.
  • IL-8 agent as an antiviral agent against herpes viruses selected from the group including, but not limited to, EBV, HSV-1, HSV-2, CMV, VZV, HHV-6, HHV-7 and HHV-8; and in a method for the prophylaxis or treatment of infections caused by such herpes viruses.
  • IL-8 agent as an antiviral agent against other human and animal viruses, including, but not limited to, porcine enteroviruses belonging to the picornaviridae or bovine diarrhea virus belonging to the togaviridae family, or bovine respiratory syncytial virus belonging to the paramyxoviridae .
  • IL-8 agent as an antiviral agent in the treatment of viral infections in humans and animals in association with other antiviral agents, including, but not limited to, interferon- ⁇ , - ⁇ , - ⁇ , tumor necrosis factor ⁇ , ganciclovir, acyclovir, vidarabine, idoxuridine, and prostaglandins or prostaglandin analogs.
  • IL-8 agent as an antiviral agent for the prophylaxis and treatment of cancers induced by oncoviruses such as retroviruses (excluding HIV-1 and HIV-2), papillo aviruses , adenoviruses and herpesviruses .
  • IL-8 agent as an antiviral agent against cancers induced by oncoviruses in association with other anticancer agents including, but not limited to, adriamycine, cyclophospha ide and methotrexate .
  • IL-8 agent as an antiviral agent for the prophylaxis and treatment of viral infections in immunosuppressed patients and animals.
  • Immunosuppressed patients include patients who have undergone organ or tissue transplantation and are treated with immunosuppressive agents including, but not limited to, azathioprine, corticosteroids, adriamycine, cyclophosphamide and methotrexate. Immunosuppressed patients also include patients with any form of cancer or neoplasic diseases treated or not with anticancer chemotherapeutic agents including but not limited to adriamycine, cyclophosphamide and methotrexate. Immunosuppressed patients also include patients with inflammatory diseases treated with antiinflammatory agents including but not limited to corticosteroids, methotrexate, azathioprine and cyclophosphamide. Immunosuppressed patients also include patients with shock or severe trauma including but not limited to burn injury, or patients undergoing chronic hemodialysis .
  • immunosuppressive agents including, but not limited to, azathioprine, corticosteroids, adriamycine
  • IL-8 agent as an antiviral agent against viral infections in immunosuppressed patients and animals in association with other antiviral agents.
  • an antiviral pharmaceutical formulation comprising a pharmacologically acceptable, therapeutically effective amount of an interleukin-8 agent, in association with a pharmaceutically acceptable carrier.
  • a method for the prophylaxis or treatment of a viral infection in a human or animal comprising administering to a human or animal in need of such treatment, a pharmacologically acceptable, therapeutically effective amount of an interleukin-8 agent .
  • Figs. 1A to IF illustrate the inhibitory effect of IL-8 on EBV-induced tumor growth and splenomegaly in SCID mice.
  • Figs. 2A, 2B and 2C illustrate the effects of IL-8 arid Gro ⁇ on EBV-induced Ca ⁇ + mobilization in human neutrophils .
  • Figs. 3A and 3B illustrate the effects of pertussis toxin on EBV-induced Ca 2+ mobilization (A) and RNA synthesis (B) in human neutrophils.
  • the IL-8 agent of the present invention is IL-8 in the 72 amino acid form [Ser IL-8J 2 or the 77 amino acid form [Ala IL-8377, derivatives or analogs of [Ser IL-8]72 or [Ala IL-8] . It is known in the art that minor addition or deletion of amino acids to IL-8 may slightly alter, viz. enhancing or decreasing the activity of IL-8. Accordingly, derivatives and analogs of IL-8 also includes modified peptides showing significant biological activity analogous to that of IL-8 in various biological systems. Significant biological activity in the context of the invention includes but is not limited to antiviral activity similar to that of IL-8.
  • the term IL-8 agent includes such biologically active variants of [Ser IL-8J 2 or [Ala IL-8] 77 .
  • Analogs or derivatives (variants) of [Ser IL- 8] 72 or [Ala IL-8J77 are defined as molecules in which the amino acid sequence or other feature of native [Ser IL-8J72 or [Ala I -8J77 has been modified covalently or noncovalently .
  • variants may or may not have a molecular weight of approximately 10 kD (as determined by SDS-PAGE carried out in the absence of a reducing agent such as ⁇ -mercaptoethanol or dithiothreitol ) .
  • Amino acid sequence variants include not only allelic relatives of [Ser IL-8172 or [Ala IL-8]77, but also predetermined mutations thereof.
  • amino acid sequence variants have an amino acid sequence with at least about 80% homology, and more typically at least about 90% homology, to that of the native [Ser IL-8J72 or [Ala IL-8177- Henceforth, the term IL-8 agent shall mean either the native sequence or a variant form unless otherwise appropriate.
  • an [Ala IL-8]77 having the human [Ala IL-8J7 amino acid sequence as set forth in adv. Immunol . ( Adv. Immunol . 55: 97, 1994), analogous [Ala IL-8]7 proteins from other species such as bovine, equine, porcine, ovine, canine, urine, feline [Ala IL-8]77 and the like, and biologically active amino acid sequence variants of these [Ala IL-81 7 molecules, including alleles and in vi tro-generated covalent derivatives of [Ala IL-8J7 proteins that demonstrate its biological activity.
  • IL-8 agent Derivatives and amino acid sequence variants of IL-8 agent are useful for their biological activity as it relates to therapeutic utility, as is set forth elsewhere herein.
  • Covalent modifications of the IL-8 agent are included within the scope of the present invention. Such modifications may be introduced into the molecule by reacting targeted amino acid residues of the purified or crude protein with an organic derivatizing agent that is capable of reacting with selected side chains or terminal residues. The resulting covalent derivatives may have altered biological activity and/or bioavailability .
  • the covalently modified IL-8 agent can be a pro-drug with reduced biological activity which upon in vi vo administration is slowly transformed into a more active molecule ( underivatized IL-8 agent).
  • Variants may also be metabolically more stable and biologically active analogs of IL-8 agents altered in a way that will result in retarded disposition of the compound (decreased metabolism and/or elimination). Sequence Modification
  • Amino acid sequence variants of [Ser IL-8J72 or [Ala I -8]77 can also be prepared. Such variants include, for example, deletions from, or insertions or substitutions of, residues within the amino acid sequences of native [Ser I -8]72 or [Ala IL-8]77- Any combination of deletion, insertion, and substitution may also be made to produce a variant having the desired activity.
  • these variants ordinarily are prepared by site-directed mutagenesis of nucleotides in the DNA encoding the [Ala IL-8J77, thereby producing DNA encoding the variant, and thereafter expressing the DNA in a recombinant cell culture.
  • the variants typically exhibit the same qualitative biological activity as the naturally occurring analog.
  • hetero- and homodimer ⁇ wherein one or both subunits are variants. Where both subunits are variants, the changes in amino acid sequence can be the same or different for each subunit chain.
  • Heterodimers are readily produced by cotransforming host cells with DNA encoding both subunits and, if necessary, purifying the desired heterodimer, or by separately synthesizing the subunits, dissociating the subunits, mixing the dissociated subunits, and then reassociating the subunits .
  • IL-8 agent also includes antibodies to the IL-8 receptors, or anti-idiotypic antibodies to antibodies raised against IL-8 or one of the above- mentioned analogs or variants of IL-8, which elicit an IL-8-like biological response, such as an antiviral effect .
  • the term IL-8 agent also includes the IL-8 receptors (types A and B) or other receptors which bind IL-8, or peptides corresponding to selected regions of these receptors or proteins (or glycoproteins or lipoproteins ) of the viral envelope or peptides corresponding to selected regions of these proteins, which prevent the binding of viral particles to the IL-8 receptors or to other receptors which bind IL-8.
  • IL-8 agent also includes analogs or variants of the IL-8 receptors (or of other receptors which bind IL-8); analogs or variants of peptides corresponding to selected regions of these receptors; analogs and variants of proteins (or glycoproteins or lipoproteins ) of the viral envelope, or of peptides corresponding to selected regions of these proteins.
  • IL-8 agent however does not include peptides of about 17 amino acids having the following formula:
  • Xaa ⁇ is Gin, Met, or Val ;
  • Xaa2 is lie, or Val; aa3 is Lys, Gin, or Ser;
  • Xaa4 is Thr, or lie
  • Xaa5 is Tyr, Leu, Met, His, Val, or Thr;
  • Xaag is Ser, Gin, Thr, or Ala
  • Xaa7 is Lys, Arg, or His
  • Xaag is absent or is Pro, Phe, or Gly;
  • Xaag is absent or is Phe, lie, or Val;
  • Xaa ⁇ is absent or is His, Lys, or Arg;
  • Xaa ⁇ i is absent or is Pro, Leu, or Phe;
  • Xaa ⁇ 2 is absent or is Lys, His or Arg.
  • viral infections which may be treated with the IL-8 agent, in accordance with the invention, are infections caused by human and animal viruses.
  • human and animal viruses is intended to include, without limitation, DNA and RNA viruses in general and Retroviridae other than HIV-1 and HIV-2.
  • DNA viruses include, without limitation, parvoviridae, papovaviridae, adenoviridae, herpesviridae, poxviridae and hepadnaviridae.
  • RNA viruses include, without limitation, retroviridae picornaviridae, togaviridae, orthomyxoviridae, paramyxoviridae, coronaviridae, reoviridae, oncornaviridae and filoviridae.
  • EBV-infected B95-8 cells 60 x 10 6 were injected intraperitoneally (IP) into SCID mice. At the indicated times, mice were treated with recombinant IL- 8. After 49 days, mice were sacrificed and autopsied. Each group consisted of 3 mice. IL-8 was always administered as a 25 ⁇ g bolus (IP) per mouse, in solution in NaCl 0.9% containing 0.1% BSA.
  • mice treated with B95-8 cells alone showed a significant inflammation of the peritoneal cavity as assessed by the occurrence of abdominal swelling, and had diarrhea, a characteristic of tumor growth in this model.
  • such symptoms were not observed in mice treated 5 times with 25 ⁇ g of IL-8 at one week intervals (group 6).
  • mice treated with 25 ⁇ g IL-8 for 6 consecutive days (group 5), the diarrhea was observed at four weeks post infection but was less severe than in infected untreated animals (group 3).
  • mice treated only once with 25 ⁇ g IL-8 (group 2), the peritoneal inflammation and diarrhea observed at four weeks post infection was as severe as in infected untreated animals of group 3.
  • mice (2) treated with NaCl glucose + 0.1% BSA
  • mice Group 3 EBV-infected mice (10) treated with NaCl:glucose + 0.1% BSA
  • mice All animals received 40 X 10 human PBMCs (in 0.5 ml PBS, i.p. injection). Five days later, animals of groups 3 and 4 were infected with EBV (0.5 X 10 TFU/mouse, i.p. injection) and all animals were treated with saline or with IL-8 on days 0, 6, 13, 20 and 27. IL-8 was always administered as 25 ⁇ g bolus (i.p.) in solution in NaCl .-glucose + 0.1% BSA. After 31 days of treatment, mice were sacrificed. The results are shown in Table 3 below. At days 22-23 post-infection, some animals of group 3 showed symptoms of infections, and from days 24- 25, lethality was observed.
  • mice treated with NaCl:glucose + 0.1% BSA or with IL-8 alone were detected in mice treated with NaCl:glucose + 0.1% BSA or with IL-8 alone (groups 1 and 2).
  • EBV has recently been shown to interact with human neutrophils in vi tro and to modulate RNA and protein synthesis.
  • IL-8 is known to induce shape change and a transient rise of the intracellular free Ca 2+ concentration ([Ca 2+ ]i) in human neutrophils.
  • EBV induces a similar but not identical (different kinetic of Ca 2+ accumulation) effect on [Ca 2+ ]i in isolated human neutrophils.
  • IL-8 EBV-induced rise in [Ca 2+ ]i in neutrophils.
  • Ca ⁇ - + mobilization was monitored in human neutrophils loaded with the fluorescent probe FURA-2/AM and treated with IL-8 or Gro ⁇ prior to or after exposure to EBV.
  • IL-8 triggers or amplifies natural antiviral mechanisms, such as the production of tumor necrosis factor alpha (TNF ⁇ ) or interferons.
  • TNF ⁇ tumor necrosis factor alpha
  • IL-8 might prevent the virus-target cell interaction either through competition for the binding site (steric hindrance) or induction of receptor internalization.
  • chemokine receptor-related proteins are encoded by various viruses and expressed on plasma membrane of infected cells.
  • BLR-1 probably identical to EBI-2
  • BLR-2 identical to EBI-1 receptors in transformed cells, which are G- protein-coupled receptors highly homologous to the IL-8 receptor.
  • cytokine receptors homologous to IL-8 receptors on EBV-infected cells may render the infected cells, the B cells which do not carry IL-8 receptors, susceptible to a putative antiviral activity of IL-8.
  • an interleukin-8 agent will vary with the nature or the severity of the condition to be treated, with the particular IL-8 agent, with the concommitant use of other active compounds and its route of administration and will be determined based on clinical judgement. It will also vary according to the age, weight and response of the individual patient.
  • An effective dosage amount of the IL-8 agent can thus be determined by pharmacokinetic studies by the clinician after a consideration of all the criteria and use of best judgment on the patient's behalf. In a general manner, the effective dosage is of about 1 to 100 nM in the blood. Accordingly, the clinician will administer a dosage that will produce such concentration in the blood .
  • any suitable route of administration may be employed for providing a mammal, especially a human with an effective dosage of an IL-8 agent of the present invention.
  • the dosage may be administered orally, parenterally, topically, intraarterially, intraperitoneally, intraveneously, intrapleurally, intraoccularly, by injection, subcutaneously or the like. It is understood that injection comprises also perfusion and continuous infusion. Dosage forms include tablets, capsules, powders, solutions, dispersions, suspensions, crams, ointments and aerosols.
  • the pharmaceutical compositions of the present invention comprise an IL-8 agent as an active ingredient, and a pharmaceutically acceptable carrier and optionally other therapeutic ingredients.
  • compositions include compositions suitable for oral or parenteral administration. Conveniently they are presented in unit dosage form and prepared by any of the methods well-known in the art of pharmacy.
  • the unit dosage form may be a slow released unit dosage form.
  • the IL-8 agent can be combined as the active ingredient in intimate admixture with a pharmaceutical carrier according to conventional pharmaceutical compounding techniques .
  • the carrier may take a wide variety of forms depending on the form of preparation desired for administration.
  • any of the usual pharmaceutical media may be employed, such as, for example, water, glycols, oils, alcohols, flavoring agents, preservatives, coloring agents and the like in the case of oral liquid preparations, such as, for example, suspensions, elixirs and solutions; or carriers such as starches, sugars, microcrystalline cellulose, diluents, granulating agents, lubricants, binders, disintegrating agents and the like in the case of oral solid preparations such as, for example, powders, capsules and tablets. Because of their ease of administration, tablets and capsules represent the most advantageous oral dosage unit form in which case solid pharmaceutical carriers are employed. If desired, tablets may be coated by standard aqueous or nonaqueous techniques .
  • compositions of the present invention suitable for oral administration may be presented as discrete units such as capsules, cachets or tablets each containing a predetermined amount of the IL-8 agent, as a powder or granules or as a solution or a suspension in an aqueous liquid, a non- aqueous liquid, an oil-in-water emulsion or a water-in- oil emulsion-
  • Such compositions may be prepared by any of the methods of pharmacy such methods including the step of bringing the IL-8 agent into association with the carrier which includes one or more necessary ingredients.
  • the compositions are prepared by uniformly and intimately admixing the IL-8 agent with liquid carriers or finely divided solid carriers or both, and then, if necessary, shaping the product into the desired presentation.
  • a tablet may be prepared by compression or molding, optionally with one or more accessory ingredients.
  • Compressed tablets may be prepared by compressing in a suitable machine, the active ingredient in a free-flowing form such as powder or granules, optionally mixed with a binder, lubricant, inert diluent, surface active or dispersing agent.
  • Molded tablets may be made by molding in a suitable machine, a mixture of the powdered compound moistened with an inert liquid diluent.
  • the IL-8 agent is to be administered in pharmacologically or physiologically acceptable amounts, by which is to be understood amounts not harmful to the patient, or amounts where any harmful side effects in individual patients are outweighed by the benefits.
  • the IL-8 agent is to be administered in a therapeutically effective amount, which is to be understood is an amount meeting the intended therapeutic objectives, and providing the benefits available from administration of interleukin-8 agent.
  • mice Female SCID-CB17 mice (Charles River, St. Constant, Canada) aged 8 weeks were used in this study. Six groups of three mice each were formed, infected with EBV-transformed cells and treated or not with IL- 8, as summarized in Table 1 above (groups 3 to 6). At day 0, B95-8 cells (60 x 10 6 ) were injected intraperitoneally (IP) into SCID mice. When indicated, mice also received one or more injections (IP) of IL-8 (groups 2, 4 to 6 ) (25 ⁇ g/mouse/injection) ( Peprotech Inc., Rocky Hid, NJ ) . The IL-8 used was the 72 amino acid form and was used in solution in NaCl 0.9% containing 0.1% BSA.
  • IP intraperitoneally
  • Fig. 1A illustrates non infected untreated mice (group 1).
  • Figs. IB and IC illustrate EBV-infected mice treated with one injection of IL-8 30 min after infection with B95-8 cells (group 4).
  • Figs. IB and IC show the abdominal cavity of the same animal, Fig. IC being a close-up photography (group 4).
  • Figs. ID and IE illustrate EBV-infected mice treated weekly with IL- 8 during four successive weeks beginning 30 min after infection with B95-8 cells (group 6).
  • Fig. IF illustrates abdominal cavity of EBV-infected mice treated once with IL-8 (left), four times with IL-8 (middle) and untreated (right).
  • Lymphopheresis was performed on a healthy human volunteer. Cells were collected during one (1) hour and purified on Ficoll gradients at 750 X g for 25 minutes. PBMCs were then washed in PBS and injected intraperitoneally (i.p.) (40 X 10 6 cells/0.5 ml
  • mice PBS/mouse mice into C.B.-17/SCID mice (4-5 week old). Five (5) days later, mice were divided in four (4) groups and the animals were infected by i.p. injection of EBV
  • IL-8 as indicated in Table 2. IL-8 was used in solution in NaCl:glucose containing 0.1% BSA. After four (4) weeks of treatment, mice were killed by cervical dislocation and autopsied. Tissues of interest were taken and kept frozen for molecular analysis . I N VI TR O S T U D I E S
  • Neutrophil suspensions (10 x 10 ⁇ cells/ml) were incubated with the fluorescent probe Fura- 2/acetoxymethyl ester (Molecular Probe, Eugene, OR) (1 ⁇ M for 30 min at 37 °C). The cells were then washed free of the extracellular probe and resuspended in Hank's balanced salt solution (HBSS) containing 1.6 mM calcium and supplemented with 10 mM HEPES. Suspensions of Fura-2-loaded cells were treated with EBV (10 6 transforming units [TFU]/mD and with IL-8 or Gro ⁇ dOO nM) in different sequences. Fluorescence (Figs.
  • EBV strain B95-8 was monitored (excitation and emission wavelengths, 340 and 510 nm, respectively) using an Aminco-Bowman, series 2 Apparatus (SLM-Aminco, Rochester, NY).
  • Viral preparations of EBV strain B95-8 were produced as previously described. Briefly, B95-8, which were mycoplasma-free tested, were grown in RPMI 1640 medium supplemented with 10% heat-inactivated FBS . When the viability of the cells were found to be less than 20%, cell-free culture supernatants were harvested and filtered through a 0.45 mm pore size filter, and the viral particles were further purified by ultracentrifugation.
  • Fig. 2A a: Gro ⁇ (100 nM) ; b: EBV; c: I -8 (100 nM) Fig.
  • 2B a: Gro ⁇ (100 nM); b: IL-8 (100 nM); c: EBV Fig. 2C: a: EBV 1/10 dilution, 10 5 TFU/ml; b: EBV; c: Gro ⁇ (100 nM) ; d: IL-8 (100 nM)
  • C pretreatment with pertussis toxin and stimulation with IL-8
  • d pretreatment with pertussis toxin and stimulation with EBV.
  • EBV-induced RNA synthesis was studied by measurement of the incorporation of [5- ⁇ H] uridine into total RNA.
  • Neutrophils (5 x 10 6 cells/ml) pretreated or not with pertussis toxin (0.5 mg/ml) were suspended in HBSS buffer supplemented with 1% heat-inactivated (1 h, 56 °C) autologous plasma.
  • One hundred ml aliquotes of the cell suspensions were incubated in 96-well microtiter plates in the presence of 1 mCi of [5- ⁇ H] uridine (per sample) and treated with 3 nM of GM-CSF (positive control) or with infectious EBV (10 6 TFU/ml).
  • GM-CSF granulocyte-macrophage colony-stimulating factor

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

La présente invention concerne l'utilisation d'une interleukine 8 (IL-8) comme agent de traitement d'une infection virale causée par un virus humain ou animal ou d'un cancer causé par un virus oncogène. L'agent IL-8 peut être une protéine IL-8 ou un analogue de ladite protéine ayant une activité biologique IL-8. L'infection virale peut provenir d'un virus à ADN sélectionné dans le groupe constitué par parvoviridae, papovaviridae, adenoviridae, herpesviridae, proxviridae et hepadnaviridae, ou d'un virus à ARN sélectionné dans le groupe constitué par retroviridae (à l'exclusion de VIH-1 et VIH-2), picornaviridae, togaviridae, orthomyxoviridae, paramyxoviridae, coronaviridae, reoviridae, oncornaviridae et filoviridae.
PCT/CA1997/000479 1996-07-05 1997-07-04 Interleukine 8 utilisee comme agent antiviral ou anticancereux WO1998001150A1 (fr)

Priority Applications (7)

Application Number Priority Date Filing Date Title
JP10504609A JP2000514066A (ja) 1996-07-05 1997-07-04 抗ウイルス性抗腫瘍剤としてのインターロイキン―８
DE69718911T DE69718911T2 (de) 1996-07-05 1997-07-04 Interleukin - 8 als antivirale- und antitumorwirkstoffe
AT97929060T ATE232108T1 (de) 1996-07-05 1997-07-04 Interleukin - 8 als antivirale- und antitumorwirkstoffe
NZ333605A NZ333605A (en) 1996-07-05 1997-07-04 Use of interleukin-8 (IL-8) as an antiviral and antitumor agent
AU33314/97A AU713675B2 (en) 1996-07-05 1997-07-04 Interleukin-8 as an antiviral and antitumor agent
EP97929060A EP0909178B1 (fr) 1996-07-05 1997-07-04 Interleukine 8 utilisee comme agent antiviral ou anticancereux
BR9710206A BR9710206A (pt) 1996-07-05 1997-07-04 Uso de um agente de interleucina-8 e formulação farmacéutica antiviral

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/674,633 1996-07-05
US08/674,633 US5900235A (en) 1996-07-05 1996-07-05 Interleukin-8 as an antiviral and antitumor agent

Publications (1)

Publication Number Publication Date
WO1998001150A1 true WO1998001150A1 (fr) 1998-01-15

Family

ID=24707360

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CA1997/000479 WO1998001150A1 (fr) 1996-07-05 1997-07-04 Interleukine 8 utilisee comme agent antiviral ou anticancereux

Country Status (12)

Country Link
US (1) US5900235A (fr)
EP (1) EP0909178B1 (fr)
JP (1) JP2000514066A (fr)
KR (1) KR20000023562A (fr)
AT (1) ATE232108T1 (fr)
AU (1) AU713675B2 (fr)
BR (1) BR9710206A (fr)
CA (1) CA2258697A1 (fr)
DE (1) DE69718911T2 (fr)
ES (1) ES2191842T3 (fr)
NZ (1) NZ333605A (fr)
WO (1) WO1998001150A1 (fr)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7067046B2 (en) 2000-08-04 2006-06-27 Essen Instruments, Inc. System for rapid chemical activation in high-throughput electrophysiological measurements
US7201836B2 (en) 1997-12-17 2007-04-10 Molecular Devices Corporation Multiaperture sample positioning and analysis system
US7244349B2 (en) 1997-12-17 2007-07-17 Molecular Devices Corporation Multiaperture sample positioning and analysis system
US7270730B2 (en) 2000-08-04 2007-09-18 Essen Instruments, Inc. High-throughput electrophysiological measurement system

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6962971B2 (en) * 2001-03-16 2005-11-08 The Regents Of The University Of California Chemokines and methods for inducing the differentiation of fibroblasts to myofibroblasts
AU2003287217B2 (en) * 2002-10-24 2010-03-04 Paratek Pharmaceuticals, Inc. Methods of using substituted tetracycline compounds to modulate RNA
JPWO2005051405A1 (ja) * 2003-11-25 2007-06-14 株式会社カネカ Ｉｌ−８産生促進剤とその用途
KR20230086610A (ko) 2021-12-07 2023-06-15 재단법인 아산사회복지재단 Il-12를 발현하는 재조합 백시니아 바이러스 및 이의 용도

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996009062A1 (fr) * 1994-09-23 1996-03-28 University Of Nebraska Board Of Regents Agonistes et antagonistes polypeptidiques de l'interleukine-8 humaine

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996009062A1 (fr) * 1994-09-23 1996-03-28 University Of Nebraska Board Of Regents Agonistes et antagonistes polypeptidiques de l'interleukine-8 humaine

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
MACKEWICZ C. ET AL.: "CD8+ Cell Anti-HIV Activity: Nonlytic Suppression of Virus replication", AIDS RESEARCH AND HUMAN RETROVIRUSES, vol. 8, no. 6, June 1992 (1992-06-01), pages 1039 - 1050, XP002042706 *
MORI N ET AL: "Production of Interleukin 8 in Adult T-Cell Leukemia Cells: Possible Transactivation of the Interleukin 8 Gene by Human T-Cell Leukemia Virus Type I tax.", CANCER RESEARCH 55 (16). 1995. 3592-3597, XP002042708 *
WUYTS A ET AL: "Leukocyte recruitment by monocyte chemotactic proteins (MCPs) secreted by human phagocytes.", JOURNAL OF IMMUNOLOGICAL METHODS 174 (1-2). 1994. 237-247, XP002042707 *

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7201836B2 (en) 1997-12-17 2007-04-10 Molecular Devices Corporation Multiaperture sample positioning and analysis system
US7244349B2 (en) 1997-12-17 2007-07-17 Molecular Devices Corporation Multiaperture sample positioning and analysis system
US7387715B2 (en) 1997-12-17 2008-06-17 Molecular Devices Corporation Sample positioning and analysis system
US7067046B2 (en) 2000-08-04 2006-06-27 Essen Instruments, Inc. System for rapid chemical activation in high-throughput electrophysiological measurements
US7270730B2 (en) 2000-08-04 2007-09-18 Essen Instruments, Inc. High-throughput electrophysiological measurement system

Also Published As

Publication number Publication date
EP0909178A1 (fr) 1999-04-21
CA2258697A1 (fr) 1998-01-15
JP2000514066A (ja) 2000-10-24
ATE232108T1 (de) 2003-02-15
US5900235A (en) 1999-05-04
DE69718911T2 (de) 2003-12-24
AU3331497A (en) 1998-02-02
BR9710206A (pt) 1999-08-10
DE69718911D1 (de) 2003-03-13
EP0909178B1 (fr) 2003-02-05
NZ333605A (en) 2000-12-22
AU713675B2 (en) 1999-12-09
ES2191842T3 (es) 2003-09-16
KR20000023562A (ko) 2000-04-25

Similar Documents

Publication Publication Date Title
Huang et al. Dengue virus infects human endothelial cells and induces IL-6 and IL-8 production.
DE69203443T2 (de) Verwendung von interleukin-10 in der adoptive immunotherapie von krebs.
US5145677A (en) Process for treatment of diseases
JPH0680583A (ja) 抗ウイルス剤として用いるための繊維芽細胞成長因子及び硫酸化多糖を含有する共働性組成物
EP0909178B1 (fr) Interleukine 8 utilisee comme agent antiviral ou anticancereux
EP0573538B1 (fr) Peptides a usage therapeutique
Ito et al. Tumor necrosis factor enhances replication of human immunodeficiency virus (HIV) in vitro
Tsang et al. Partial restoration of impaired interleukin-2 production and Tac antigen (putative interleukin-2 receptor) expression in patients with acquired immune deficiency syndrome by isoprinosine treatment in vitro.
US7399825B2 (en) Synthetic peptide, inhibitor to DNA viruses
Gratama et al. Detection of multiple Epstein‐Barr viral strains in allogeneic bone marrow transplant recipients
US7335727B2 (en) Pharmaceutical used for treating HIV infection, the composition and uses thereof
JP3520084B2 (ja) 多発性硬化症を含めた炎症の治療におけるペプチドｔ及びその関連ペプチド類
JP2938916B2 (ja) ヘルペスウィルスの増殖阻害および潜伏感染後の再発阻止剤
O'Brien et al. Assessment of antiviral activity, efficacy, and toxicity of prostaglandin A2 in a rabbit model of herpetic keratitis
Delannoy et al. Role of Interferon Alpha (IFN‐α) and Interferon Gamma (IFN‐γ) in the Control of the Infection of Monocyte‐Like Cells with Human Cytomegalovirus (HCMV)
Ohmann et al. A neutrophil-derived antiviral protein: induction requirements and biological properties
HK1021624A (en) Interleukin-8 as an antiviral and antitumor agent
CN113440603A (zh) 人α干扰素亚型及受体结合相关位点突变体在制备防治新型冠状病毒感染药物中的用途
CN1225016A (zh) 一种抗病毒和抗肿瘤药－白细胞介素－8
CN116003258B (zh) 12-o-辛酰基-佛波醇酯类衍生物及制备方法和应用
Wybran et al. Isoprinosine (inosiplex): immunological and clinical effects
JP2589094B2 (ja) 抗悪性腫瘍剤
WO1997025350A1 (fr) Utilisation de chemokines pour le traitement et la prevention de l'infection a vih
CN115073561A (zh) vMIP提高Tcm CD8+T细胞水平及在防治新冠肺炎病毒感染的药物中的应用
JPH08333274A (ja) 悪性腫瘍治療用キット

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 97196176.X

Country of ref document: CN

AK Designated states

Kind code of ref document: A1

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH HU IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW AM AZ BY KG KZ MD RU TJ TM

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH KE LS MW SD SZ UG ZW AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
ENP Entry into the national phase

Ref document number: 2258697

Country of ref document: CA

Ref document number: 2258697

Country of ref document: CA

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 333605

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 1997929060

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 1019997000005

Country of ref document: KR

Ref document number: PA/A/1999/000256

Country of ref document: MX

WWP Wipo information: published in national office

Ref document number: 1997929060

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: 1019997000005

Country of ref document: KR

WWG Wipo information: grant in national office

Ref document number: 1997929060

Country of ref document: EP

WWR Wipo information: refused in national office

Ref document number: 1019997000005

Country of ref document: KR